The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer

Clinical and Translational Oncology

Volumn 17, Issue 6, 2015, Pages 462-468

  Kim, S T ^a   Do, I G ^a   Lee, J ^a   Sohn, I ^b   Kim, K M ^a   Kang, W K ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

Epidermal growth factor receptor (EGFR); Gastric cancer; Human epidermal growth factor 2 (HER2); Immunohistochemistry; N Methyl N nitrosoguanidine human osteosarcoma transforming gene (MET); NanoString

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; AUTOMATIC SLIDE STAINER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SCREENING; CANCER SURGERY; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MOTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ANALYZER; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NANOANALYSIS; NANOSTRING BASED MULTIGENE ASSAY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STOMACH CANCER; AREA UNDER THE CURVE; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROTO ONCOGENE; SEQUENCE ANALYSIS; STOMACH NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAPECITABINE; EVEROLIMUS; FEMALE; GENES, ERBB-1; GENES, ERBB-2; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; ROC CURVE; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA; STOMACH NEOPLASMS;

EID: 84930087970     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1258-7     Document Type: Article

References (29)

1. Cunningham D, Jost LM, Purkalne G, Oliveira J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol. 2005;16(Suppl 1):i22–3.
2. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419–24.
3. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012;44:11–24.
4. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.
5. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:1357–62.
6. Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist’s view. Br J Cancer. 2004;91:11–7.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.
8. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
11. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013;39:793–801.
12. Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araujo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol. 2013;19:6383–97.
13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.
14. Jimeno A, Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol. 2005;53:179–92.
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
16. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, et al. c-Met expression in gastric cancer with liver metastasis. Oncology. 2002;63:286–96.
17. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D’Emidio S, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011;29:4789–95.
18. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 2011;25:1517–24.
19. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.
20. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012;30:3287–96.
21. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317–25.
22. Lee SJ, Lee J, Lee J, Park SH, Park JO, Park YS, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs. 2013;31:1580–6.
23. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499–508.
24. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–50.
25. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013;26:1632–41.
26. Cho EY, Choi YL, Han JJ, Kim KM, Oh YL. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int. 2008;58:17–25.
27. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist. 2011;16:1706–13.
28. Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013;44:380–9.
29. Lee J, Kim S, Kim P, Liu X, Lee T, Kim KM, et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One. 2013;8:e54644.